## BAX: Baxter International Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.0% below STRENGTH zone (3.0-6.0%); PEG 33.66 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($17.62)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Class Action Lawsuit Reminder from Pomerantz LLP for Shareholders of Baxter International, Inc. â€“ BAX**
- Source: WJTV | 20251202T070000 | Neutral | Relevance: 99%
- Pomerantz LLP has issued a reminder about a class action lawsuit filed against Baxter International, Inc. (NYSE: BAX) concerning alleged securities fraud or unlawful business practices. Shareholders who purchased Baxter securities during the Class Period have until December 15, 2025, to seek appointment as Lead Plaintiff. The lawsuit stems from Baxter's announcement on July 31, 2025, to voluntarily and temporarily pause shipments of its Novum LVP medical device, which led to a significant drop in its stock price.

**2. Levi & Korsinsky Moves to SueWallSt For Baxter International, Inc. Investors That Lost Money**
- Source: WDHN | 20251202T171500 | Neutral | Relevance: 99%
- Levi & Korsinsky has filed a class-action lawsuit against Baxter International, Inc. on behalf of investors who incurred losses due to alleged securities fraud between February 23, 2022, and July 30, 2025. The firm encourages affected investors to contact them for more information regarding the lawsuit. Levi & Korsinsky, with 20 years of experience, specializes in representing investors in complex securities litigation.

**3. Baxter International, Inc. (BAX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit**
- Source: FOX40 News | 20251202T120000 | Neutral | Relevance: 99%
- The Law Offices of Frank R. Cruz announce a securities fraud class action lawsuit against Baxter International, Inc. (BAX) concerning alleged systemic defects in its Novum LVP medical devices. Shareholders who incurred losses between February 23, 2022, and July 30, 2025, have the opportunity to lead the lawsuit, with a lead plaintiff deadline of December 15, 2025. The lawsuit claims Baxter failed to disclose widespread malfunctions, serious patient risks, and inadequate remedial efforts related to the devices.

**4. Investors in Baxter International, Inc. Should Contact Levi**
- Source: GlobeNewswire | 20251201T161600 | Neutral | Relevance: 99%
- Levi & Korsinsky, LLP has filed a class action securities lawsuit against Baxter International, Inc. (NYSE: BAX) on behalf of investors who suffered losses due to alleged securities fraud between February 23, 2022, and July 30, 2025. The lawsuit claims Baxter made false statements regarding defects in its Novum LVP product, which caused patient harm and financial repercussions for the company. Investors have until December 15, 2025, to request to be appointed as lead plaintiff.

**5. Portnoy Law Firm Announces Class Action on Behalf of Baxter International, Inc. Investors**
- Source: CBS 42 | 20251202T090000 | Neutral | Relevance: 99%
- The Portnoy Law Firm has announced a class action lawsuit against Baxter International, Inc. on behalf of investors who purchased securities between February 23, 2022, and July 30, 2025. The lawsuit alleges that Baxter made false and misleading statements regarding systemic defects in its Novum IQ Large Volume Pump, which led to malfunctions and patient harm. Following Baxter's announcement to temporarily pause shipments of the Novum LVP, the company's stock price fell by over 22%.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $15 | $19 | -21% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.16M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 15.1% (+14.9%)
- Vanguard Group Inc: 12.2% (+0.5%)
- Dodge & Cox Inc.: 11.2% (+10.1%)
- Pzena Investment Man: 11.2% (+45.9%)
- State Street Corpora: 4.3% (+0.3%)

### Key Risks

1. Valuation stretched: PEG 33.7x requires aggressive growth execution.
2. Elevated short interest (9.7%): bears positioning against stock.
3. Long-term trend broken: trading 30.7% below SMA200.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 33.66 signals overvaluation risk, limited margin of safety. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.4B |
| Beta | 0.61 |
| 52W Range | $17.40 - $37.74 |
| Short Interest | 9.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 33.66 |
| Forward P/E | 8.2 |
| Current P/E | 8.0 |
| YoY Growth | -2.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.1% to -0.0% (-1.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.0pp (needs >3.0% for momentum thesis). Below SMA200 (0.69x), long-term trend not supportive. RSI neutral at 46.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.04% (CS: 68) | Neutral |
| RSI_14 | 45.8 | Neutral |
| MACD Histogram | 0.28 | Bullish |
| vs SMA20 | 1.031x | Above |
| vs SMA50 | 0.909x | Below |
| vs SMA200 | 0.693x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $18.84
- **Stop Loss:** $17.62 (6.5% risk)
- **Target:** $20.06 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 819
- **Position Value:** $15,429.96
- **Portfolio %:** 15.43%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-19 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.60 | $0.69 | +15.4% |
| 2025Q2 | $0.61 | $0.54 | -11.5% |
| 2025Q1 | $0.48 | $0.55 | +13.8% |
| 2024Q4 | $0.53 | $0.58 | +9.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*